Effect of Trichostatin A on Anti HepG2 Liver Carcinoma Cells: Inhibition of HDAC Activity and Activation of Wnt/β-Catenin Signaling

  • Shi, Qing-Qiang (Laboratory of Stem Cell and Tissue Engineering, Department of Histology and Embryology, Chongqing Medical University) ;
  • Zuo, Guo-Wei (Laboratory of Clinical Diagnostics, Chongqing Medical University) ;
  • Feng, Zi-Qiang (Laboratory of Stem Cell and Tissue Engineering, Department of Histology and Embryology, Chongqing Medical University) ;
  • Zhao, Lv-Cui (Laboratory of Stem Cell and Tissue Engineering, Department of Histology and Embryology, Chongqing Medical University) ;
  • Luo, Lian (Laboratory of Stem Cell and Tissue Engineering, Department of Histology and Embryology, Chongqing Medical University) ;
  • You, Zhi-Mei (Laboratory of Stem Cell and Tissue Engineering, Department of Histology and Embryology, Chongqing Medical University) ;
  • Li, Dang-Yang (Laboratory of Stem Cell and Tissue Engineering, Department of Histology and Embryology, Chongqing Medical University) ;
  • Xia, Jing (Laboratory of Stem Cell and Tissue Engineering, Department of Histology and Embryology, Chongqing Medical University) ;
  • Li, Jing (Laboratory of Stem Cell and Tissue Engineering, Department of Histology and Embryology, Chongqing Medical University) ;
  • Chen, Di-Long (Laboratory of Stem Cell and Tissue Engineering, Department of Histology and Embryology, Chongqing Medical University)
  • Published : 2014.10.11


Purpose: To investigate the effect of deacetylase inhibitory trichostatin A (TSA) on anti HepG2 liver carcinoma cells and explore the underlying mechanisms. Materials and Methods: HepG2 cells exposed to different concentrations of TSA for 24, 48, or 72h were examined for cell growth inhibition using CCK8, changes in cell cycle distribution with flow cytometry, cell apoptosis with annexin V-FTIC/PI double staining, and cell morphology changes under an inverted microscope. Expression of ${\beta}$-catenin, HDAC1, HDAC3, H3K9, CyclinD1 and Bax proteins was tested by Western blotting. Gene expression for ${\beta}$-catenin, HDAC1and HDAC3 was tested by q-PCR. ${\beta}$-catenin and H3K9 proteins were also tested by immunofluorescence. Activity of Renilla luciferase (pTCF/LEF-luc) was assessed using the Luciferase Reporter Assay system reagent. The activity of total HDACs was detected with a HDACs colorimetric kit. Results: Exposure to TSA caused significant dose-and time-dependent inhibition of HepG2 cell proliferation (p<0.05) and resulted in increased cell percentages in G0/G1 and G2/M phases and decrease in the S phase. The apoptotic index in the control group was $6.22{\pm}0.25%$, which increased to $7.17{\pm}0.20%$ and $18.1{\pm}0.42%$ in the treatment group. Exposure to 250 and 500nmol/L TSA also caused cell morphology changes with numerous floating cells. Expression of ${\beta}$-catenin, H3K9and Bax proteins was significantly increased, expression levels of CyclinD1, HDAC1, HDAC3 were decreased. Expression of ${\beta}$-catenin at the genetic level was significantly increased, with no significant difference in HDAC1and HDAC3 genes. In the cytoplasm, expression of ${\beta}$-catenin fluorescence protein was not obvious changed and in the nucleus, small amounts of green fluorescence were observed. H3K9 fluorescence protein were increased. Expression levels of the transcription factor TCF werealso increased in HepG2 cells following induction by TSA, whikle the activity of total HDACs was decreased. Conclusions: TSA inhibits HDAC activity, promotes histone acetylation, and activates Wnt/${\beta}$-catenin signaling to inhibit proliferation of HepG2 cell, arrest cell cycling and induce apoptosis.


Supported by : National Natural Science Foundation of China


  1. Bai L, Merchant JL (2007). A role for CITED2, a CBP/p300 interacting protein, in colon cancer cell invasion. FEBS Letters, 581, 5904-10.
  2. Barbetti V, Gozzini A, Cheloni G, et al (2013). Time- and residue-specific differences in histone acetylation induced by VPA and SAHA in AML1/ETO-positive leukemia cells. Epigenetics, 8, 210-9.
  3. Chen W-Q, Xu B, Mao J-W, et al (2014). Inhibitory effects of $\alpha$-pinene on hepatoma carcinoma cell proliferation. Asian Pac J Cancer Prev, 15, 3293-7.
  4. Cui J, Zhou X, Liu Y, et al (2001). Mutation and overexpression of the $\beta$-catenin gene may play an important role in primary hepatocellular carcinoma among Chinese people. J Cancer Res Clin Oncol, 127, 577-81.
  5. Dahmani R, Just PA, Perret C (2011). The Wnt/$\beta$-catenin pathway as a therapeutic target in human hepatocellular carcinoma. Clin Res Hepatol Gastroenterol, 35, 709-13.
  6. Debeb BG, Lacerda L, Xu W, et al (2012). Histone deacetylase inhibitors stimulate dedifferentiation of human breast cancer cells through WNT/$\beta$-catenin signaling. Stem Cells, 30, 2366-77.
  7. Feng D, Wu J, Tian Y, et al (2013). Targeting of histone deacetylases to reactivate tumour suppressor genes and its therapeutic potential in a human cervical cancer xenograft model. PLoS One, 8, 80657-68.
  8. Fujisawa K, Maesawa C, Sato R, et al (2005). Epigenetic status and aberrant expression of the maspin gene in human hepatobiliary tract carcinomas. Lab Invest, 85, 214-24.
  9. Haghshenas MR, Arabi M, Mousavi T (2014). Hepatitis B genotypes in iran. Mater Sociomed, 26, 129-33.
  10. Herold C, Ganslmayer M, Ocker M, et al (2002). The histonedeacetylase inhibitor Trichostatin A blocks proliferation and triggers apoptotic programs in hepatoma cells. J Hepatol, 36, 233-40.
  11. Iguchi H, Urashima Y, Inagaki Y, et al (2007). SOX6 suppresses cyclin D1 promoter activity by interacting with $\beta$-catenin and histone deacetylase 1, and its down-regulation induces pancreatic $\beta$-cell proliferation. J Biol Chem, 282, 19052-61.
  12. Ji Z, Wang T, Shao Z, et al (2014). A population-based study examining hepatitis B virus infection and immunization rates in Northwest China. PLoS One, 9, 97474-84.
  13. Ker CG, Chen JS, Kuo KK, et al (2011). Liver surgery for hepatocellular carcinoma: laparoscopic versus open approach. Int J Hepatol, 2011, 596792.
  14. Lazarova DL, Bordonaro M, Carbone R, et al (2004). Linear relationship between Wnt activity levels and apoptosis in colorectal carcinoma cells exposed to butyrate. Int J Cancer, 110, 523-31.
  15. Lee JE, Bae SH, Choi JY, et al (2014). Epirubicin, cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma. World J Gastroenterol, 20, 235-41.
  16. Li J-P, Cao N-X, Jiang R-T, et al (2014). Knockdown of GCF2/LRRFIP1 by RNAi causes cell growth inhibition and increased apoptosis in human hepatoma HepG2 cells. Asian Pac J Cancer Prev, 15, 2753-8.
  17. Marks P, Rifkind RA, Richon VM, et al (2001). Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer, 1, 194-202.
  18. Miyahara K, Nouso K, Yamamoto K (2014). Chemotherapy for advanced hepatocellular carcinoma in the sorafenib age. World J Gastroenterol, 20, 4151-9.
  19. Miyoshi H, Deguchi A, Nakau M, et al (2009). Hepatocellular carcinoma development induced by conditional $\beta$-catenin activation in Lkb1+/- mice. Cancer Sci, 100, 2046-53.
  20. Mosimann C, Hausmann G, Basler K (2009). Beta-catenin hits chromatin: regulation of Wnt target gene activation. Nat Rev Mol Cell Biol, 10, 276-86.
  21. Myzak MC, Karplus PA, Chung FL, et al (2004). A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase. Cancer Res, 64, 5767-74.
  22. Osaki A, Suda T, Kamimura K, et al (2013). A safe and effective dose of cisplatin in hepatic arterial infusion chemotherapy for hepatocellular carcinoma. Cancer Med, 2, 86-98.
  23. Page AJ, Cosgrove DC, Philosophe B, et al (2014). Hepatocellular carcinoma: diagnosis, management, and prognosis. Surg Oncol Clin N Am, 23, 289-311.
  24. Pathil A, Armeanu S, Venturelli S, et al (2006). HDAC inhibitor treatment of hepatoma cells induces both TRAILindependent apoptosis and restoration of sensitivity to TRAIL. Hepatology, 43, 425-34.
  25. Quint K, Agaimy A, Di Fazio P, et al (2011). Clinical significance of histone deacetylases 1, 2, 3, and 7: HDAC2 is an independent predictor of survival in HCC. Virchows Arch, 459, 129-39.
  26. Scaggiante B, Kazemi M, Pozzato G, et al (2014). Novel hepatocellular carcinoma molecules with prognostic and therapeutic potentials. World J Gastroenterol, 20, 1268-88.
  27. Shao N, Zou J, Li J, et al (2012). Hyper-activation of WNT/$\beta$-catenin signaling pathway mediates anti-tumor effects of histone deacetylase inhibitors in acute T lymphoblastic leukemia. Leuk Lymphoma, 53, 1769-78.
  28. Song W-F, Wang L, Huang W-Y, et al (2013). MiR-21 upregulation induced by promoter zone histone acetylation is associated with chemoresistance to gemcitabine and enhanced malignancy of pancreatic cancer cells. Asian Pac J Cancer Prev, 14, 7529-36.
  29. Tanase A-M, Dumitrascu T, Dima S, et al (2014). Influence of hepatitis viruses on clinico-pathological profiles and long-term outcome in patients undergoing surgery for hepatocellular carcinoma. Hepatobiliary Pancreatic Dis Int, 13, 162-72.
  30. Thompson MD, Monga SP (2007). WNT/$\beta$-catenin signaling in liver health and disease. Hepatology, 45, 1298-305.
  31. Tsai WL, Lai KH, Liang HL, et al (2014). Hepatic arterial infusion chemotherapy for patients with huge unresectable hepatocellular carcinoma. PLoS One, 9, 92784.
  32. Venturelli S, Armeanu S, Pathil A, et al (2007). Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma. Cancer, 109, 2132-41.
  33. Wiltse J (2005). Mode of Action: Inhibition of histone deacetylase, altering WNT-dependent gene expression, and regulation of beta-catenin-developmental effects of valproic acid. Crit Rev Toxicol, 35, 727-38.
  34. Woo HJ, Lee SJ, Choi BT, et al (2007). Induction of apoptosis and inhibition of telomerase activity by trichostatin A, a histone deacetylase inhibitor, in human leukemic U937 cells. Exp Mol Pathol, 82, 77-84.
  35. Xu L-B (2010). Staging systems for predicting survival of patients with hepatocellular carcinoma after surgery. World Journal of Gastroenterology, 16, 5257.
  36. Yang XJ, Seto E (2007). HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene, 26, 5310-8.
  37. Ying Y, Tao Q (2009). Epigenetic disruption of the WNT/$\beta$-catenin signaling pathway in human cancers. Epigenetics, 4, 307-12.
  38. Zhang Q-C, Jiang S-J, Zhang S, et al (2012). Histone deacetylase inhibitor trichostatin a enhances antitumor effects of docetaxel or erlotinib in A549 cell line. Asian Pac J Cancer Prev, 13, 3471-6.

Cited by

  1. Clinical significance of STAT3 and MAPK phosphorylation, and the protein expression of cyclin D1 in skin squamous cell carcinoma tissues vol.12, pp.6, 2012,
  2. Differentially Expressed Genes in Metastatic Advanced Egyptian Bladder Cancer vol.16, pp.8, 2015,
  3. Clinical significance of the phosphorylation of MAPK and protein expression of cyclin D1 in human osteosarcoma tissues vol.15, pp.4, 2017,
  4. Short hairpin RNA silencing of TGF-βRII and FZD-7 synergistically suppresses proliferation and metastasis of hepatocellular carcinoma cells vol.11, pp.3, 2016,